Provided by Tiger Trade Technology Pte. Ltd.

Perspective Therapeutics

4.71
+0.08001.73%
Post-market: 4.720.0089+0.19%19:57 EST
Volume:1.72M
Turnover:8.02M
Market Cap:536.94M
PE:-3.25
High:4.78
Open:4.72
Low:4.45
Close:4.63
52wk High:6.16
52wk Low:1.60
Shares:114.00M
Float Shares:102.00M
Volume Ratio:0.19
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4506
EPS(LYR):-1.2306
ROE:-37.26%
ROA:-17.24%
PB:2.22
PE(LYR):-3.83

Loading ...

Perspective Therapeutics Raises Capital to Advance Radiopharmaceutical Pipeline

TIPRANKS
·
Feb 04

Perspective Therapeutics Raises $175 Million in Stock and Pre-Funded Warrant Offering

Reuters
·
Feb 02

Perspective Therapeutics Inc - Prices 39,576,088 Shares at $3.79 Each

THOMSON REUTERS
·
Feb 02

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Feb 02

Perspective Therapeutics Inc - Net Proceeds to Advance Clinical Development and Invest in Facilities

THOMSON REUTERS
·
Feb 02

Perspective Therapeutics Highlights Progress in Radiopharmaceutical Pipeline

TIPRANKS
·
Feb 02

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
Jan 30

Perspective Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $12 From $10

THOMSON REUTERS
·
Jan 30

Perspective Therapeutics (CATX) Gets a Buy from Wedbush

TIPRANKS
·
Jan 13

Perspective Therapeutics Price Target Maintained With a $14.00/Share by BTIG

Dow Jones
·
Jan 13

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Myriad Genetics (MYGN)

TIPRANKS
·
Jan 13

Perspective Therapeutics outlines 2026 clinical and manufacturing priorities

TIPRANKS
·
Jan 12

Perspective Therapeutics Announces Plans to Advance Clinical Pipeline, Expand Manufacturing Capacity, and Present Updated Data at 2026 Medical Conferences

Reuters
·
Jan 12

Perspective Therapeutics Advances VMT-α-NET Clinical Program with Strong Patient Recruitment and Positive Early Results

Reuters
·
Jan 12

Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data

TIPRANKS
·
Jan 09

Perspective Therapeutics Reports Positive Interim Results for [212Pb]VMT-α-NET in Neuroendocrine Tumor Trial

Reuters
·
Jan 09

Perspective Therapeutics Presents Updated Interim Data of [212PB]Vmt-Α-Net in Its Ongoing Phase 1/2a Clinical Trial at the 2026 Asco Gastrointestinal Cancers Symposium

THOMSON REUTERS
·
Jan 09

Perspective Therapeutics Reports Promising [212Pb]VMT-α-NET Data in Neuroendocrine Tumor Trial

Reuters
·
Dec 04, 2025

Perspective Therapeutics (CATX) Receives a Buy from Roth MKM

TIPRANKS
·
Nov 28, 2025

Perspective Therapeutics (CATX) Receives a Buy from RBC Capital

TIPRANKS
·
Nov 26, 2025